These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 18996314)

  • 1. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications of dendritic cell vaccines.
    Morse MA; Lyerly HK
    Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E
    Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
    Matera L
    Cancer Treat Rev; 2010 Apr; 36(2):131-41. PubMed ID: 19954892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
    Qi SY; Wang M; Xu Y
    Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
    Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
    Eymard JC; Gervais A; Jarcau R; Bernard J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
    Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
    Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
    Lin AM; Hershberg RM; Small EJ
    Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.